Current Build

4.4.2.16621 HL7 v3 Value Set ActSubstanceAdminSubstitutionCode

Vocabulary Work Group Maturity Level: 1Draft Use Context: Any

This value set (http://terminology.hl7.org/ValueSet/v3-ActSubstanceAdminSubstitutionCode) is defined as part of HL7 v3.

Summary

Defining URL:http://terminology.hl7.org/ValueSet/v3-ActSubstanceAdminSubstitutionCode
Version:2014-03-26
Name:v3.ActSubstanceAdminSubstitutionCode
Title:V3 Value SetActSubstanceAdminSubstitutionCode
Definition:

No Description Provided

OID:2.16.840.1.113883.1.11.16621 (for OID based terminology systems)
Source ResourceXML / JSON

This value set is used in the following places:


This value set includes codes from the following code systems:

 

This expansion generated 17 Jun 2019


This value set contains 9 concepts

Expansion based on http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution version 2018-08-12

All codes from system http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution

CodeDisplayDefinition
EequivalentDescription: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
ECequivalent compositionDescription: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
BCbrand compositionDescription: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven
Ggeneric compositionDescription: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
TEtherapeutic alternativeDescription: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet
TBtherapeutic brandDescription: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet
TGtherapeutic genericDescription: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine
FformularyDescription: This substitution was performed or is permitted based on formulary guidelines.
NnoneNo substitution occurred or is permitted.